{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T05:17:32Z","timestamp":1734758252536,"version":"3.32.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Myasthenia gravis (MG) is a rare autoimmune disorder with significant clinical implications, including life-threatening myasthenic crises and exacerbations. Understanding real-world treatment patterns, especially associated direct medical costs, is essential for the effective management of healthcare delivery.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a descriptive cohort study using health administrative claims data from the Czech Republic covering more than 1,500 prevalent MG patients. Data were analysed for healthcare resource utilization, medication costs, and hospitalization rates related to MG and its complications.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Acetylcholine inhibitors and corticosteroids were widely prescribed, with 91.1% and 75.2% of patients receiving them at least once, respectively. Immunosuppressive therapy was given to 45.2% of patients. Myasthenic crises occurred in 2% of patients, with a mean hospitalization cost of 21,020 EUR, while exacerbations occurred in 9.2% of patients, with lower costs (5,951 EUR per hospitalization). Outpatient intravenous immunoglobulin and plasma exchange therapies incurred additional costs of 20,700 EUR and 18,206 EUR per person-year, respectively. The mean total cost per patient-year was 1,271 EUR, with significant cost differences among patients with different treatment patterns.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study offers real-world insights into the treatment patterns and associated direct medical costs of MG in the Czech Republic. Myasthenic crises and exacerbations pose considerable cost burdens, while outpatient therapies and common pharmacotherapies are less costly. These findings are vital for healthcare planning, economic evaluation, and resource allocation, potentially leading to enhanced patient care and outcomes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-024-03504-3","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T12:36:53Z","timestamp":1734698213000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Myasthenia gravis: understanding treatment patterns and direct medical costs in the Czech Republic"],"prefix":"10.1186","volume":"19","author":[{"given":"Gleb","family":"Donin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karla","family":"Mothejlov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magda","family":"Hor\u00e1kov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanislav","family":"Vohanka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"key":"3504_CR1","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40273-020-00912-8","volume":"38","author":"E Landfeldt","year":"2020","unstructured":"Landfeldt E, Pogoryelova O, Sejersen T, Zethraeus N, Breiner A, Lochm\u00fcller H. Economic costs of myasthenia gravis. Syst Rev PharmacoEconomics. 2020;38:715\u201328. https:\/\/doi.org\/10.1007\/s40273-020-00912-8","journal-title":"Syst Rev PharmacoEconomics"},{"key":"3504_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/mus.26114","volume":"58","author":"NM Engel-Nitz","year":"2018","unstructured":"Engel-Nitz NM, Boscoe A, Wolbeck R, Johnson J, Silvestri NJ. Burden of illness in patients with treatment refractory myasthenia gravis. Muscle Nerve. 2018;58:99\u2013105. https:\/\/doi.org\/10.1002\/mus.26114","journal-title":"Muscle Nerve"},{"key":"3504_CR3","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ana.22139","volume":"68","author":"A Mandawat","year":"2010","unstructured":"Mandawat A, Kaminski HJ, Cutter G, Katirji B, Alshekhlee A. Comparative analysis of therapeutic options used for myasthenia gravis. Ann Neurol. 2010;68:797\u2013805. https:\/\/doi.org\/10.1002\/ana.22139","journal-title":"Ann Neurol"},{"key":"3504_CR4","doi-asserted-by":"publisher","unstructured":"Hughes T, Anderson AEL, Habib AA, Perez K, Bergin C, Suchotliff S, et al. Impact of social determinants of health on individuals living with generalized myasthenia gravis and implications for patient support programs. Front Public Health. 2023;11. https:\/\/doi.org\/10.3389\/fpubh.2023.1147489","DOI":"10.3389\/fpubh.2023.1147489"},{"key":"3504_CR5","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1186\/s12967-021-03185-7","volume":"19","author":"N Salari","year":"2021","unstructured":"Salari N, Fatahi B, Bartina Y, Kazeminia M, Fatahian R, Mohammadi P, et al. Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis. J Translational Med. 2021;19:516. https:\/\/doi.org\/10.1186\/s12967-021-03185-7","journal-title":"J Translational Med"},{"key":"3504_CR6","doi-asserted-by":"crossref","unstructured":"Ignatova V, Kostadinov K, Vassileva E, Muradyan N, Stefanov G, Iskrov G et al. Socio-economic burden of myasthenia gravis: a cost-of-illness study in Bulgaria. Front Public Health. 2022;10.","DOI":"10.3389\/fpubh.2022.822909"},{"key":"3504_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.25122\/jml-2020-0145","volume":"14","author":"A-M Bubuioc","year":"2021","unstructured":"Bubuioc A-M, Kudebayeva A, Turuspekova S, Lisnic V, Leone MA. The epidemiology of myasthenia gravis. J Med Life. 2021;14:7\u201316. https:\/\/doi.org\/10.25122\/jml-2020-0145","journal-title":"J Med Life"},{"key":"3504_CR8","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.3390\/jcm10112235","volume":"10","author":"L Dresser","year":"2021","unstructured":"Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med. 2021;10:2235. https:\/\/doi.org\/10.3390\/jcm10112235","journal-title":"J Clin Med"},{"key":"3504_CR9","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1111\/j.1468-1331.2012.03698.x","volume":"19","author":"M Gattellari","year":"2012","unstructured":"Gattellari M, Goumas C, Worthington JM. A national epidemiological study of myasthenia gravis in australia. Eur J Neurol. 2012;19:1413\u201320. https:\/\/doi.org\/10.1111\/j.1468-1331.2012.03698.x","journal-title":"Eur J Neurol"},{"key":"3504_CR10","doi-asserted-by":"publisher","first-page":"e16367","DOI":"10.1016\/j.heliyon.2023.e16367","volume":"9","author":"G Antonini","year":"2023","unstructured":"Antonini G, Habetswallner F, Inghilleri M, Mantegazza R, Rodolico C, Sacc\u00e0 F, et al. Real world study on prevalence, treatment and economic burden of myasthenia gravis in Italy. Heliyon. 2023;9:e16367. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e16367","journal-title":"Heliyon"},{"key":"3504_CR11","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/mus.22212","volume":"44","author":"JT Guptill","year":"2011","unstructured":"Guptill JT, Marano A, Krueger A, Sanders DB. Cost analysis of myasthenia gravis from a large U.S. insurance database. Muscle Nerve. 2011;44:907\u201311. https:\/\/doi.org\/10.1002\/mus.22212","journal-title":"Muscle Nerve"},{"key":"3504_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/cen3.12495","volume":"10","author":"H Murai","year":"2019","unstructured":"Murai H, Hasebe M, Murata T, Utsugisawa K. Clinical burden and healthcare resource utilization associated with myasthenia gravis: assessments from a Japanese claims database. Clin Experimental Neuroimmunol. 2019;10:61\u20138. https:\/\/doi.org\/10.1111\/cen3.12495","journal-title":"Clin Experimental Neuroimmunol"},{"key":"3504_CR13","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12883-022-02692-4","volume":"22","author":"L Harris","year":"2022","unstructured":"Harris L, Graham S, MacLachlan S, Exuzides A, Jacob S. A retrospective longitudinal cohort study of the clinical burden in myasthenia gravis. BMC Neurol. 2022;22:172. https:\/\/doi.org\/10.1186\/s12883-022-02692-4","journal-title":"BMC Neurol"},{"key":"3504_CR14","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.nmd.2023.02.002","volume":"33","author":"A Mevius","year":"2023","unstructured":"Mevius A, J\u00f6res L, Biskup J, Heidbrede T, Mahic M, Wilke T, et al. Epidemiology and treatment of myasthenia gravis: a retrospective study using a large insurance claims dataset in Germany. Neuromuscul Disord. 2023;33:324\u201333. https:\/\/doi.org\/10.1016\/j.nmd.2023.02.002","journal-title":"Neuromuscul Disord"},{"key":"3504_CR15","doi-asserted-by":"publisher","first-page":"e230108","DOI":"10.57264\/cer-2023-0108","volume":"13","author":"J Pisc","year":"2023","unstructured":"Pisc J, Ting A, Skornicki M, Sinno O, Lee E. Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data. J Comp Eff Res. 2023;13:e230108. https:\/\/doi.org\/10.57264\/cer-2023-0108","journal-title":"J Comp Eff Res"},{"key":"3504_CR16","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","volume":"269","author":"S Lehnerer","year":"2022","unstructured":"Lehnerer S, Jacobi J, Schilling R, Grittner U, Marbin D, Gerischer L, et al. Burden of disease in myasthenia gravis: taking the patient\u2019s perspective. J Neurol. 2022;269:3050\u201363. https:\/\/doi.org\/10.1007\/s00415-021-10891-1","journal-title":"J Neurol"},{"key":"3504_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/mus.27659","volume":"66","author":"I Lee","year":"2022","unstructured":"Lee I, Leach JM, Aban I, McPherson T, Duda PW, Cutter G. One-year follow-up of disease burden and medication changes in patients with myasthenia gravis: from the MG patient registry. Muscle Nerve. 2022;66:411\u201320. https:\/\/doi.org\/10.1002\/mus.27659","journal-title":"Muscle Nerve"},{"key":"3504_CR18","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jocn.2016.11.003","volume":"38","author":"KK Sonkar","year":"2017","unstructured":"Sonkar KK, Bhoi SK, Dubey D, Kalita J, Misra UK. Direct and indirect cost of myasthenia gravis: A prospective study from a tertiary care teaching hospital in India. J Clin Neurosci. 2017;38:114\u20137. https:\/\/doi.org\/10.1016\/j.jocn.2016.11.003","journal-title":"J Clin Neurosci"},{"key":"3504_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1159\/000529583","volume":"57","author":"H Wartmann","year":"2023","unstructured":"Wartmann H, Hoffmann S, Ruck T, Nelke C, Deiters B, Volmer T, Incidence. Prevalence, hospitalization rates, and treatment patterns in myasthenia gravis: a 10-year real-world data analysis of German claims data. Neuroepidemiology. 2023;57:121\u20138. https:\/\/doi.org\/10.1159\/000529583","journal-title":"Neuroepidemiology"},{"key":"3504_CR20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12883-022-02922-9","volume":"23","author":"T Ramsaroop","year":"2023","unstructured":"Ramsaroop T, Gelinas D, Kang SA, Govindarajan R. Analysis of length of stay and treatment emergent complications in hospitalized myasthenia gravis patients with exacerbation. BMC Neurol. 2023;23:12. https:\/\/doi.org\/10.1186\/s12883-022-02922-9","journal-title":"BMC Neurol"},{"key":"3504_CR21","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/mus.22327","volume":"45","author":"JT Guptill","year":"2012","unstructured":"Guptill JT, Sharma BK, Marano A, Soucy A, Krueger A, Sanders DB. Estimated cost of treating myasthenia gravis in an insured U.S. population. Muscle Nerve. 2012;45:363\u20136. https:\/\/doi.org\/10.1002\/mus.22327","journal-title":"Muscle Nerve"},{"key":"3504_CR22","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.3390\/ijerph18041382","volume":"18","author":"M Tambor","year":"2021","unstructured":"Tambor M, Klich J, Domaga\u0142a A. Financing healthcare in Central and Eastern European countries: how far are we from universal health coverage? Int J Environ Res Public Health. 2021;18:1382. https:\/\/doi.org\/10.3390\/ijerph18041382","journal-title":"Int J Environ Res Public Health"},{"key":"3504_CR23","doi-asserted-by":"publisher","first-page":"04160","DOI":"10.7189\/jogh.13.04160","volume":"13","author":"Y Huang","year":"2023","unstructured":"Huang Y, Li Y, Pan H, Han L. Global, regional, and national burden of neurological disorders in 204 countries and territories worldwide. J Global Health. 2023;13:04160. https:\/\/doi.org\/10.7189\/jogh.13.04160","journal-title":"J Global Health"},{"key":"3504_CR24","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1159\/000512973","volume":"55","author":"E Sobieszczuk","year":"2021","unstructured":"Sobieszczuk E, Napi\u00f3rkowski \u0141, Szczudlik P, Kostera-Pruszczyk A. Myasthenia gravis in Poland: National Healthcare Database Epidemiological Study. Neuroepidemiology. 2021;55:62\u20139. https:\/\/doi.org\/10.1159\/000512973","journal-title":"Neuroepidemiology"},{"key":"3504_CR25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000487886","volume":"50","author":"I Martinka","year":"2018","unstructured":"Martinka I, Fulova M, Spalekova M, Spalek P. Epidemiology of myasthenia gravis in Slovakia in the years 1977\u20132015. Neuroepidemiology. 2018;50:153\u20139. https:\/\/doi.org\/10.1159\/000487886","journal-title":"Neuroepidemiology"},{"key":"3504_CR26","doi-asserted-by":"publisher","first-page":"S133","DOI":"10.1016\/j.jval.2023.03.704","volume":"26","author":"Q Cai","year":"2023","unstructured":"Cai Q, Zhang Q, Borsum J, Batista A, Kunovszki P, Isheden G, et al. EE403 direct and indirect costs among employed patients with myasthenia gravis in Sweden. Value Health. 2023;26:S133. https:\/\/doi.org\/10.1016\/j.jval.2023.03.704","journal-title":"Value Health"},{"key":"3504_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00415-009-5256-6","volume":"257","author":"K Schepelmann","year":"2010","unstructured":"Schepelmann K, Winter Y, Spottke AE, Claus D, Grothe C, Schr\u00f6der R, et al. Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol. 2010;257:15\u201323. https:\/\/doi.org\/10.1007\/s00415-009-5256-6","journal-title":"J Neurol"},{"key":"3504_CR28","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40273-020-00912-8","volume":"38","author":"E Landfeldt","year":"2020","unstructured":"Landfeldt E, Pogoryelova O, Sejersen T, Zethraeus N, Breiner A, Lochm\u00fcller H. Economic costs of myasthenia gravis: a systematic review. PharmacoEconomics. 2020;38:715\u201328. https:\/\/doi.org\/10.1007\/s40273-020-00912-8","journal-title":"PharmacoEconomics"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03504-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03504-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03504-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T13:06:08Z","timestamp":1734699968000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03504-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3504"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03504-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,20]]},"assertion":[{"value":"16 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted using anonymized retrospective administrative claim data, and approval by an ethics committee was not needed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there are no competing interests associated with the research contained within this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"472"}}